Company intelligence / Profile preview

Edge Therapeutics

Berkeley Heights, New Jersey, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

Edge's lead product EG-1962 failed in Phase 3 clinical trials for aneurysmal subarachnoid hemorrhage in March 2018. The trial was halted after interim analysis showed it was unlikely to perform better than standard of care. This led to significant cost-cutting measures including layoffs.

Therapeutic areas: Neurology
Modalities: Sustained-release drug delivery systems
Industry: Biotech

Drug pipeline

2 assets

EG-1962

Discontinued

Indications: Subarachnoid hemorrhage

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Edge Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edge Therapeutics.

Explore the full profile